By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for Tirasemtiv
Email this page to a colleague
What is the development status for investigational drug Tirasemtiv?
Tirasemtiv is an investigational drug.
There have been 7 clinical trials for Tirasemtiv.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Sclerosis. The leading clinical trial sponsors are Cytokinetics, National Institute of Neurological Disorders and Stroke (NINDS), and [disabled in preview].
There are fourteen US patents protecting this investigational drug and one hundred and ten international patents.
Summary for Tirasemtiv
| US Patents | 14 |
| International Patents | 110 |
| US Patent Applications | 44 |
| WIPO Patent Applications | 21 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 2 (2016-10-01) |
| Vendors | 45 |
Recent Clinical Trials for Tirasemtiv
| Title | Sponsor | Phase |
|---|---|---|
| A Study for Patients Who Completed VITALITY-ALS (CY 4031) | Cytokinetics | Phase 3 |
| Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year | Cytokinetics | Phase 3 |
| Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) | Cytokinetics | Phase 2 |
Clinical Trial Summary for Tirasemtiv
Top disease conditions for Tirasemtiv
Top clinical trial sponsors for Tirasemtiv
US Patents for Tirasemtiv
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tirasemtiv | Get Started Free | Increase of protein synthesis ameliorates synaptopathy-related neurological disorders | Academia Sinica (Taipei, TW) | Get Started Free |
| Tirasemtiv | Get Started Free | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | Get Started Free |
| Tirasemtiv | Get Started Free | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | Get Started Free |
| Tirasemtiv | Get Started Free | Combination ALS therapy | Cytokinetics, Inc. (South San Francisco, CA) | Get Started Free |
| Tirasemtiv | Get Started Free | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | Get Started Free |
| Tirasemtiv | Get Started Free | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (Arhus N., DK) | Get Started Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tirasemtiv
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tirasemtiv | Taiwan | TW201617070 | 2034-11-03 | Get Started Free |
| Tirasemtiv | Taiwan | TWI561235 | 2034-11-03 | Get Started Free |
| Tirasemtiv | Australia | AU2017261372 | 2036-05-05 | Get Started Free |
| Tirasemtiv | Canada | CA3023278 | 2036-05-05 | Get Started Free |
| Tirasemtiv | China | CN107847398 | 2036-05-05 | Get Started Free |
| Tirasemtiv | European Patent Office | EP3452003 | 2036-05-05 | Get Started Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
